Researchers at the University of Geneva, together with colleagues in Switzerland, France, the United States and Israel, describe how optogenetic control of brain cells and circuits is already steering ...

A preclinical study uncovered a new gene therapy that targets pain centers in the brain while eliminating the risk of ...

Traditional trial start-up workflows often follow a sequential path, from feasibility to contracting, then regulatory ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

Collaboration will combine Lexeo expertise in cardiac genetic medicine with Johnson & Johnson’s expertise in cardiovascular therapeutics and ...

-- Durable disease control and quality-of-life improvements for patients with ISM in the PIONEER trial -- -- Prolonged survival, including in the first-line treatment setting, for patients with ...

Innovation in ophthalmology is often measured by what reaches the clinic—but the path to those breakthroughs begins much ...

Healthcare and therapy systems face a worsening workforce shortage, creating an urgent need for technologies that can support ...

Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with ...

Gene therapy ‘switch’ may offer non-addictive pain relief. New approach targets pain signals while leaving the rest of the brain untouched.

Healthcare and therapy systems face a worsening workforce shortage, creating an urgent need for technologies that can support or augment human roles ...